GlassScriptPhysician profile
Van Quoc Pham
NPI 1851786156
$6,274.09
in general payments reported to CMS, 2019-2025
48 companies · $189 in 2025
The $189 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $1,578 · 2021: $1,709 · 2022: $1,525 · 2023: $586 · 2024: $269 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,044.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,060.76 | 2019-2024 | Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $818.22 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $570.29 | 2021-2023 | Dupixent |
| Janssen Pharmaceuticals, INC | $429.88 | 2019-2022 | |
| Lilly USA, LLC | $404.96 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $342.39 | 2021-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $338.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $248.10 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $227.55 | 2020-2021 | |
| Janssen Biotech, INC. | $204.73 | 2019-2022 | |
| Pfizer INC. | $149.92 | 2020-2021 | |
| Therapeuticsmd, INC. | $126.90 | 2019-2022 | |
| Abbvie INC. | $109.50 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $97.35 | 2022 | |
| Pulmonx Corporation | $96.03 | 2020 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Van Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.